Plasma homocysteine in schizophrenia: Determinants and clinical correlations in Tunisian patients free from antipsychotics

Psychiatry Research

Volumn 179, Issue 1, 2010, Pages 24-29

  Bouaziz, Noomen ^a   Ayedi, Imen ^b   Sidhom, Oussama ^a   Kallel, Ameni ^b   Rafrafi, Rym ^a   Jomaa, Riadh ^b   Melki, Wahid ^a   Feki, Moncef ^b   Kaabechi, Naziha ^b   El Hechmi, Zouhaier ^a  

^a RAZI HOSPITAL   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

Author keywords

Anhedonia; Apathy; Asociality; Avolition; Folate; Methylenetetrahydrofolate reductase; Negative symptoms; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HALOPERIDOL; HOMOCYSTEINE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; AMINO ACID BLOOD LEVEL; ANHEDONIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; ENZYME POLYMORPHISM; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; MENTAL PATIENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN INTAKE; PSYCHOMETRY; SCHIZOPHRENIA; TUNISIA; BLOOD; DEMENTIA; FEMALE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS;

ADULT; DEMENTIA; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; STATISTICS AS TOPIC; TUNISIA; VITAMIN B 12;

EID: 77955418465     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.04.008     Document Type: Article

References (44)

1. Adler Nevo G., Meged S., Sela B.A., Hanoch-Levi A., Hershko R., Weizman A. Homocysteine levels in adolescent schizophrenia patients. European Neuropsychopharmacology 2006, 16:588-591.
2. Akanji A.O., Ohaeri J.U., Al-Shammri S.A., Fatania H.R. Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clinical Biochemistry 2007, 40:1026-1031.
3. Amani R. Is dietary pattern of schizophrenia patients different from healthy subjects?. BMC Psychiatry 2007, 7:15-21.
4. Applebaum J., Shimon H., Sela B.A., Belmaker R.H., Levine J. Homocysteine levels in newly admitted schizophrenic patients. Journal of Psychiatric Research 2004, 38:413-416.
5. Bolander-Gouaille C., Bottigglieri T. Homocysteine, Related Vitamins and Neuropsychiatric Disorders 2003, Springer, Paris.
6. Brown A.S., Susser E.S. Homocysteine and schizophrenia: from prenatal to adult life. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1175-1180.
7. Brown A.S., Bottiglieri T., Schaefer C.A., Quesenberry C.P., Liu L., Bresnahan M., Susser E.S. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Archives of General Psychiatry 2007, 64:31-39.
8. Donohoe G., Robertson I.H. Can specific deficits in executive functioning explain the negative symptoms of schizophrenia? A review. Neurocase 2003, 9:97-108.
9. Forsman A., Ohman R. Pharmacokinetic studies on haloperidol in man. Current Therapeutic Research, Clinical and Experimental 1976, 20:319-355.
10. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J.H., den Heijer M., Klujitmans L.A.J., van den Heuvel L.P., Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995, 10:111-113.
11. Goff D.C., Bottiglieri T., Arning E., Shih V., Freudenreich O., Evins A.E., Henderson D.C., Baer L., Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. The American Journal of Psychiatry 2004, 16:1705-1708.
12. Haidemenos A., Kontis D., Gazi A., Kallai E., Allin M., Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 3:1289-1296.
13. Jacques P.F., Bostom A.G., Wilson P.W., Rich S., Rosenberg I.H., Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. The American Journal of Clinical Nutrition 2001, 73:613-621.
14. Jarskog L.F., Gilmore J.H., Selinger E.S., Lieberman J.A. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry 2000, 48:641-650.
15. Krebs M.O., Bellon A., Mainguy G., Jay T.M., Frieling H. One-carbon metabolism and schizophrenia: current challenges and future directions. Trends in Molecular Medicine 2009, 15:562-570.
16. Labadarios D., Dickerson J.W., Parke D.V., Lucas E.G., Obuwa G.H. The effects of chronic drug administration on hepatic enzyme induction and folate metabolism. British Journal of Clinical Pharmacology 1978, 5:167-173.
17. Lee Y.S., Han D.H., Jeon C.M., Lyoo I.K., Na C., Chae S.L., Cho S.C. Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. Neuroreport 2006, 17:743-746.
18. Lerner V., Miodownik C., Kaptsan A., Vishne T., Sela B.A., Levine J. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive Parkinsonism and/or tardive dyskinesia. The Journal of Clinical Psychiatry 2005, 66:1558-1563.
19. Levine J., Stahl Z., Sela B., Gavendo S., Ruderman V., Belmaker R.H. Elevated homocysteine levels in young male patients with schizophrenia. The American Journal of Psychiatry 2002, 159:1790-1792.
20. Levine J., Stahl Z., Sela B.A., Ruderman V., Shumaico O., Babushkin I., Osher Y., Bersudsky Y., Belmaker R.H. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biological Psychiatry 2006, 60:265-269.
21. Marcadet A., O'Connel P., Cohen D. Standardized Southern blot workshop techniques. Histocompatibility testing 1987, 587-590. Springer, New York. B. Dupont (Ed.).
22. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in Neurosciences 2003, 26:137-146.
23. Morrison P.D., Murray R.M. Schizophrenia. Current Biology 2005, 15:980-984.
24. Muntjewerff J.W., Van der Put N., Eskes T., Ellenbroek B., Steegers E., Blom H., Zitman F. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Research 2003, 121:1-9.
25. Muntjewerff J.W., Hoogendoorn M.L., Kahn R.S., Sinke R.J., Den Heijer M., Kluijtmans L.A., Blom H.J. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2005, 135:69-72.
26. Muntjewerff J.W., Kahn R.S., Blom H.J., den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Molecular Psychiatry 2006, 11:143-149.
27. Neeman G., Blanaru M., Bloch B., Kremer I., Ermilov M., Javitt D.C., Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. The American Journal of Psychiatry 2005, 162:1738-1740.
28. Nyberg S., Farde L., Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Archives of General Psychiatry 1997, 54:953-961.
29. Philibert R., Gunter T., Hollenbeck N., Adams W.J., Bohle P., Packer H., Sandhu H. No association of the C677T methylenetetrahydrofolate reductase polymorphism with schizophrenia. Psychiatric Genetics 2006, 16:221-223.
30. Regland B. Schizophrenia and single-carbon metabolism. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1124-1132.
31. Regland B., Johansson B.V., Grenfeldt B., Hjelmgren L.T., Medhus M. Homocysteinemia is a common feature of schizophrenia. Journal of Neural Transmission. General Section 1995, 100:165-169.
32. Reif A., Schneider M.F., Kamolz S., Pfuhlmann B. Homocysteinemia in psychiatric disorders: association with dementia and depression, but not schizophrenia in female patients. Journal of Neural Transmission 2003, 110:1401-1411.
33. Roffman J.L., Weiss A.P., Purcell S., Caffalette C.A., Freudenreich O., Henderson D.C., Bottiglieri T., Wong D.H., Halsted C.H., Goff D.C. Contribution of methylene tetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biological Psychiatry 2008, 1:42-48.
34. Sachdev P.S. Homocysteine and brain atrophy. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1152-1161.
35. Sanchez-Villegas A., Henriquez P., Bes-Rastrollo M., Doreste J. Mediterranean diet and depression. Public Health Nutrition 2006, 9:1104-1109.
36. Sazci A., Ergul E., Guzelhan Y., Kaya G., Kara I. Methylenete trahydrofolate reductase gene polymorphisms in patients with schizophrenia. Brain Research. Molecular Brain Research 2003, 17:104-107.
37. Sazci A., Ergul E., Kucukali I., Kara I., Kaya G. Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: association is significant in men but not in women. Progress in Neuropsychopharmacology & Biological Psychiatry 2005, 29:1113-1123.
38. Shi Q., Savage J.E., Hufeisen S.J., Rauser L., Grajkowska E., Ernsberger P., Wroblewski J.T., Nadeau J.H., Roth B.L. L-homocysteine sulfinic acid and other acidichomocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. The Journal of Pharmacology and Experimental Therapeutics 2003, 305:131-142.
39. Smythies J.R. Oxidative reactions and schizophrenia: a review-discussion. Schizophrenia Research 1997, 24:357-364.
40. Susser E., Brown A.S., Klonowski E., Allen R.H., Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: a possible association. Biological Psychiatry 1998, 44:141-143.
41. Troen A.M. The central nervous system in animal models of hyperhomocysteinemia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1140-1151.
42. Tucker K.L., Qiao N., Scott T., Rosenberg I., Spiro A. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. The American Journal of Clinical Nutrition 2005, 82:627-635.
43. Vilella E., Virgos C., Murphy M., Martorell L., Valero J., Simó J.M., Joven J., Fernández-Ballart J., Labad A. Further evidence that hyperhomocysteinemia and methylene tetrahydrofolate reductase C677T and A1289C polymorphisms are not risk factors for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1169-1174.
44. Virgos C., Martorell L., Simó J.M., Valero J., Figuera L., Joven J., Labad A., Vilella E. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport 1999, 10:2035-2038.